Receptor Tyrosine Kinase Treatment Market Size & Share, by Product Type (Epidermal Growth Factor Receptor [EGFR] Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor [VEGFR] Tyrosine Kinase Inhibitors); Application (Lung Cancer, Breast Cancer, Renal Cell Cancer); Distribution (Hospital Pharmacies, Independent Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Request Free Sample Copy

Report ID: 3626
Published Date: Feb 16, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the Receptor Tyrosine Kinase Treatment Landscape

Bristol-Myers Squibb Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Boehringer Ingelheim GmbH
Eton Bioscience, Inc.
GlaxoSmithKline plc
Merck KGaA
AstraZeneca
Novartis AG
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services, Inc.

Browse Key Market Insights with Data Illustration:

Receptor Tyrosine Kinase Treatment Market Size, Growth Outlook 2035

In the News

A study conducted provided information on the potential cardiotoxicity of a list of FDA approved Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors and ranked them by their potential cardiotoxic risk associated in patients with solid tumors.
A research investigated the efficacy of EGFR-TKIs in older patients, where patients of 65 years or older with EGFR-mutated Stage IIIB–IV non-small-cell lung cancer (NSCLC) were enrolled and the efficacy and prognosis of first-line EGFR-TKI treatment was evaluated. EGFR-TKIs are standard first-line treatments for advanced EGFR-mutated non-small-cell lung cancer (NSCLC) patients.

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are surge in prevalence of obesity, growing investment in healthcare, clinical approval of kinase inhibitors, and others.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2035.

High cost of tyrosine kinase therapies, lack of funds for R&D activities, and challenges faced by clinical trials for commercialization of tyrosine kinase inhibitors are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Eton Bioscience, Inc., GlaxoSmithKline plc, and more.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product type, application, distribution channel and by region.

The breast cancer segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Companies Dominating the Receptor Tyrosine Kinase Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the receptor tyrosine kinase treatment market?

What would be the CAGR of receptor tyrosine kinase treatment market over the forecast period?

What are the challenges affecting the receptor tyrosine kinase treatment market growth?

Which region will provide more business opportunities for growth of receptor tyrosine kinase treatment market in future?

Who are the major players dominating the receptor tyrosine kinase treatment market?

How are the company profiles selected?

What are the segments in the global receptor tyrosine kinase treatment market?

Which sub-segment captures the largest market size in product type segment in the global receptor tyrosine kinase treatment market?